Log In Sign up
The largest database of trusted experimental protocols
> Physiology > Organ or Tissue Function > Insemination

Insemination

Insemination is the process of introducing semen into the female reproductive tract, typically for the purpose of achieving pregnancy.
This can be done through various methods, such as artificial insemination, in which semen is collected and then injected into the uterus or cervix, or natural insemination, which involves sexual intercourse.
Insemination is a common technique used in assisted reproductive technologies, as well as in animal breeding programs.
It is an important area of study for researchers interested in improving fertility and reproductive outcomes.

Most cited protocols related to «Insemination»

1
Multicenter RCT on Unexplained Infertility
Cited 19 times
The Assessment of Multiple Intrauterine Gestations from Ovarian Stimulation (AMIGOS) clinical trial was conducted by the National Institute of Child Health and Human Development (NICHD) Cooperative Reproductive Medicine Network; the Collaborative Center for Statistics and Science at Yale University served as the data coordinating center. The trial was conducted at 12 clinical sites throughout the United States.
The trial design has been published previously.22 (link) Briefly, this was a multicenter, randomized clinical trial involving 900 couples with unexplained infertility. Women were between 18 and 40 years of age with regular menses (nine or more cycles per year), had a normal uterine cavity with at least one patent fallopian tube, and had a male partner with a semen specimen of at least 5 million sperm per milliliter. This threshold for the sperm count was used because the protocol incorporated a sperm wash with intrauterine insemination. (World Health Organization [WHO] thresholds for normal sperm counts, which are higher, are based on intercourse rather than insemination.) In addition, a sperm wash was performed to concentrate motile sperm; this approach has been shown to improve pregnancy rates with sperm counts below the WHO threshold.23 (link)Approval for the study was obtained from the institutional review board at each site. Written informed consent was provided by all female and male participants. The first and last authors assume responsibility for the accuracy and completeness of the data reporting and for the fidelity of the report to the study protocol, which is available with the full text of this article at NEJM.org.
Diamond M.P., Legro R.S., Coutifaris C., Alvero R., Robinson R.D., Casson P., Christman G.M., Ager J., Huang H., Hansen K.R., Baker V., Usadi R., Seungdamrong A., Bates G.W., Rosen R.M., Haisenleder D., Krawetz S.A., Barnhart K., Trussell J.C., Ohl D., Jin Y., Santoro N., Eisenberg E, & Zhang H. (2015). Letrozole, Gonadotropin, or Clomiphene for Unexplained Infertility. The New England journal of medicine, 373(13), 1230-1240.
Publication 2015
Coitus Dental Caries Ethics Committees, Research Fallopian Tubes Females Insemination Males Menstruation Ovarian Stimulation Pharmaceutical Preparations Semen Sperm Sterility, Reproductive Uterus Woman
2
Canine Model of GRMD Disorder
Cited 11 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2011
Animals Biological Assay Childbirth Females Heart Immunofluorescence Insemination Luteinizing hormone Males Ovulation Plant Embryos Progesterone Sequoia Serum Skeletal Muscles Tissues Vagina
3
CRISPR-Cas9 Mediated Genome Editing in Mice
Cited 10 times
BDF1 and C57BL6/JJcl (hereafter termed B6) mice were purchased from CLEA Japan Inc. (Tokyo, Japan) and bred with a light period of 7:00 to 19:00. All animal experiments were carried out according to the ethical guidelines of Shinshu University.
Fertilized eggs were collected using a standard in vitro fertilization (IVF) method [23 (link)]. Briefly, ovulated oocytes were collected from 4- to 10-week-old BDF1 females superovulated by injection with 5 IU of equine chorionic gonadotropin (peamex; Novartis Animal Health Inc., Tokyo, Japan) and 5 IU of human chorionic gonadotropin (Gonatropin; ASKA Pharmaceutical Co., Ltd., Tokyo, Japan) at a 48-h interval and inseminated with B6 spermatozoa obtained from the cauda epididymides of 8- to 10-week-old males. Successfully fertilized eggs were identified by the presence of both pronuclei and the second polar body at 6–7 h after insemination.
Cas9mRNA, R2gRNA, and the R2HR DNA donor fragment were microinjected using a method previously described by Sakurai et al. [23 (link)]. Briefly, approximately 2 pL of a 2-template mixture (containing 100 or 200 μg/mL of Cas9mRNA and 50 μg/mL of R2gRNA) or 3-template mixture (containing 10 μg/mL of R2HR, 100 or 200 μg/mL of Cas9mRNA, and 50 μg/mL of R2gRNA) was injected into the pronucleus and/or cytoplasm using a standard microinjection system (Narishige-Olympus MMO-202ND, MM-89, UT-2, IM-9B, and IX-70; Narishige Group, Ltd., Tokyo, Japan). Injected eggs were then cultured in 30 μL of KSOM medium [24 (link)] covered with paraffin oil at 37°C in an atmosphere of 5% CO2 up to the blastocyst stage. EGFP fluorescence was monitored at the blastocyst stage using an Olympus IX70 inverted fluorescence microscope with the U-MWIBA2 filter set (Olympus, Tokyo, Japan).
Sakurai T., Watanabe S., Kamiyoshi A., Sato M, & Shindo T. (2014). A single blastocyst assay optimized for detecting CRISPR/Cas9 system-induced indel mutations in mice. BMC Biotechnology, 14, 69.
Full text: Click here
Publication 2014
Animals Atmosphere Blastocyst Culture Media Cytoplasm Eggs Epididymis Equine Gonadotropins Females Fertilization in Vitro Fluorescence Human Chorionic Gonadotropin Hypomenorrhea Insemination Males Mice, House Microinjections Microscopy, Fluorescence Ovum paraffin oils Pharmaceutical Preparations Polar Bodies Sperm Tissue Donors Zygote
4
Reproductive Fitness Impacts of Stressors on Mosquitoes
Cited 9 times
Various parameters of reproductive fitness of females were assessed following an uninfected or infected bloodmeal, or an infected meal given to mosquitoes that had been additionally stressed. Stresses were designed to simulate conditions in the field by (1) maintenance at the lower temperature of 20°C for 12 h each night, (2) removing glucose for 12 h each night, and (3) subjecting the cage to vigorous cage movements to induce flight for 2h on days 1 and 2. Starvation and lowered temperature stresses were applied simultaneously every night and flight was induced during the daytime. Tests were carried out on the Keele strain prior to any selection and on the 12th or 13th selection generations of all lines. The number of larvae produced by each mosquito was also monitored at generation 9.
Mass sibling-mating took place on emergence, and insemination rates were checked in 30 females on days 4–6 by examining the spermathecae. Another 120 females were removed from the stock cages and fed on an uninfected or P. y. nigeriensis-infected mouse. S, R, and C lines were fed on the same mouse to minimize variations in gametocyte density or blood factors such as hematocrit. Approximately 100 fully engorged females from each group were kept individually until hematin had been excreted (usually day 2 after feeding), then those still alive were moved to oviposition pots. Eggs were counted within 24 h of oviposition. Egg hatching success was determined by assessing the proportion of larvae that hatched from each egg batch. On day 4 post-hatching, 40 larvae from each female were chosen randomly and reared to pupation in standardised conditions. Larval survival, first and last day of pupation, percentage pupation, and, in the initial experiments, imago wing lengths were noted and significant differences determined by a chi-squared test.
On day 6–7 after feeding, females were dissected and ovaries were examined for retained eggs. Midguts of infected females were examined for the presence and density of oocysts, and wing length was measured as an indicator of mosquito size (Ahmed et al. 1999 ). Bloodmeal size was expressed in terms of hematin excreted with reference to bovine hematin standards (Hogg and Hurd 1997 (link)).
Hurd H., Taylor P.J., Adams D., Underhill A, & Eggleston P. (2005). EVALUATING THE COSTS OF MOSQUITO RESISTANCE TO MALARIA PARASITES. Evolution; international journal of organic evolution, 59(12), 2560-2572.
Publication 2005
Cattle Culicidae Eggs Females Glucose Hematin Insemination Larva Marijuana Abuse Mice, House Movement Oocysts Ovary Oviposition Reproductive Fitness Strains vascular factor Volumes, Packed Erythrocyte
5
Predicting Blastocyst Formation and Quality
Cited 8 times
The KIDScore algorithm was tested on morphokinetic data from a separate group of 11 218 embryos cultured to Day 5, using AUC as the principal measure of predictive capability of blastocyst formation and quality. Data were collected from 31 clinics between 2010 and 2014 and were not overlapping with any of the data used in the development of the algorithms investigated in this study, see Table I for details. As for the data used for developing the KIDScore algorithm, the clinics agreed to share data for time periods from one to several years and no specific methods were applied in the selection of these clinics. Only data from embryos exhibiting at least one cell division were included.
There was overlap at the clinic level which provided data from Day 3 cycles used for developing the KIDScore algorithm and from Day 5 cycles for predicting blastocyst development, but independence at the patient and treatment levels. Here, blastocyst formation was defined as whether or not an embryo had reached the stage of a fully developed blastocyst at 120 h post insemination. A subset of the embryos (n = 4136) was classified at 114–120 h post insemination using Gardner's scoring criteria (Gardner and Schoolcraft, 1999 ). For simplification, three groups were created for inclusion in the analysis: top quality (TQ), good quality (GQ) and poor quality (PQ) blastocysts. The TQ group was comprised of 3AA, 4AA and 5AA blastocysts, and the GQ group was comprised of 3/4/5BB, AB or BA. Blastocysts with scorings below those of the GQ group were classified as PQ. The above three groups are in accordance with Cetinkaya et al. (2015) (link). The blastocyst quality was further categorized in two groups; TQ and GQ blastocysts versus PQ blastocysts.
Petersen B.M., Boel M., Montag M, & Gardner D.K. (2016). Development of a generally applicable morphokinetic algorithm capable of predicting the implantation potential of embryos transferred on Day 3. Human Reproduction (Oxford, England), 31(10), 2231-2244.
Publication 2016
Blastocyst Division, Cell Embryo Insemination Patients

Most recents protocols related to «Insemination»

1
Preterm Birth and Neonatal Outcomes Analysis
Preterm birth was the primary outcome of this study, which was defined as births before 37 completed weeks of gestation. The World Health Organization (WHO) further subdivided preterm birth based on gestational age: extremely preterm (< 28 weeks), very preterm (28 to < 32 weeks), and moderate or late preterm (32 to < 37 weeks) [23 (link)]. Secondary outcomes were NICU admission, low birthweight and small for gestational age. Low birthweight was defined as a birthweight < 2500 g, and small for gestational age was defined as a birthweight less than the 10th percentile. The following variables were collected: maternal age at delivery (years), race [Asian, Black (Black or African American), White, other (American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, and more than one race)], education [less than 12 grade, high school/general educational development (GED), some college or associate degree (AA), bachelor or higher], pre-pregnancy weight (lb), pre-pregnancy body mass index (BMI) (BMI < 18.5 kg/m2, underweight; BMI = 18.5–24.9 kg/m2, normal; BMI = 25.0–29.9 kg/m2, overweight; BMI = 30.0–34.9 kg/m2, obesity), delivery weight (lb), weight gain (lb), smoking before pregnancy (yes or no), smoking status 1st/2nd/3rd trimester (mother-reported smoking in the three trimesters of pregnancy, yes or no), hypertension eclampsia (yes or no), gestational hypertension (yes or no), pre-pregnancy hypertension (yes or no), number of prenatal visits, the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC, receipt of WIC food for the mother during this pregnancy, yes or no), plurality, prior birth now living, prior birth now dead, prior other terminations, total birth order, gestational age (weeks), newborn sex (female or male), birth weight (g), infertility treatment used (yes or no), pregnancy method (natural pregnancy, pregnancy via ART), method of delivery [spontaneous, non-spontaneous (forceps, vacuum, cesarean)], preterm birth [extremely preterm, very preterm, moderate or late preterm; spontaneous, indicated (forceps, vacuum, cesarean)], NICU admission, low birthweight (yes or no), and small for gestational age (yes or no). WIC is a program intended to help low income pregnant women, infants, and children through age 5 receive proper nutrition by providing vouchers for food, nutrition counseling, health care screenings and referrals; it is administered by the U.S. Department of Agriculture (https://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/DVS/natality/UserGuide2019-508.pdf). Infertility treatment referred to using fertility enhancing drugs, artificial insemination, intrauterine insemination, or using ART. ART included in vitro fertilization (IVF), gamete intrafallopian transfer (GIFT), and zygote intrafallopian transfer (ZIFT). Information on variables is available at https://www.cdc.gov/nchs/nvss/index.htm.
Lu L., He L., Hu J, & Li J. (2023). Association between very advanced maternal age women with gestational diabetes mellitus and the risks of adverse infant outcomes: a cohort study from the NVSS 2014–2019. BMC Pregnancy and Childbirth, 23, 158.
Full text: Click here
Publication 2023
African American Alaskan Natives American Indians Artificial Insemination Asian Americans Birth Birth Weight Child Eclampsia Fertility Agents Fertilization in Vitro Food Forceps Gamete Intrafallopian Transfer Gestational Age High Blood Pressures Index, Body Mass Infant Infant, Newborn Insemination Males Mothers Native Hawaiians Obesity Obstetric Delivery Pacific Islander Americans Pregnancy Pregnant Women Prehypertension Premature Birth Screening Sterility, Reproductive Transient Hypertension, Pregnancy Vacuum Woman Zygote Intrafallopian Transfer
2
Ovarian Stimulation Protocols: A Comparative Evaluation
Ovarian stimulation protocols included gonadotropin-releasing hormone (GnRH) agonist protocol, GnRH antagonist protocol, and progestin-primed ovarian stimulation (PPOS) protocol. Recombinant human chorionic gonadotropin (OVIDREL; Merck Serono, Darmstadt, Germany) or GnRH-a (Decapeptyl; Ferring, Saint-Prex, Switzerland) were administered in patients when two leading follicles reached 18 mm in diameter. Oocyte retrieval was performed at 36 h after recombinant human chorionic gonadotropin or GnRH-a triggered by transvaginal ultrasound-guided aspiration. Insemination method was selected according to the sperm count after sperm preparation. A morphologic score of cleavage-stage embryo was given based on the number of blastomeres, the homogeneous degree of blastomeres, and the degree of cytoplasmic fragmentation, which has been extensively described in our previous study (3 (link)). If a couple has two or more high-quality cleavage-stage embryos on day 3 of embryo culture, the embryos were selected and cultured to blastocyst stage. Blastocyst evaluation was performed according to the Gardner’s grading system (4 (link)).
For patients who underwent GnRH agonist protocol and GnRH antagonist protocol, one to two fresh embryos were transferred into the uterus of women free of OHSS, hydrosalpinx, intrauterine adhesion and high progesterone level (> 1.5 ng/ml) on the day of triggering, and then, the spare embryos were cryopreserved for the next FET. Patients who underwent PPOS protocol had to freeze all their embryos. The vitrified cryopreservation was conducted according to standard protocols, as previously described (5 (link)).
Fan L., Li N., Liu X., Li X., Cai H., Pan D., Wang T., Shi W., Qu P, & Shi J. (2023). Hormone replacement treatment regimen is associated with a higher risk of hypertensive disorders of pregnancy in women undergoing frozen-thawed embryo transfer. Frontiers in Endocrinology, 14, 1133978.
Full text: Click here
Publication 2023
Blastocyst Blastomeres Cleavage Stage, Ovum Cryopreservation Cytoplasm Decapeptyl Embryo Freezing Gonadorelin Hair Follicle Human Chorionic Gonadotropin Insemination Oocyte Retrieval Ovarian Hyperstimulation Syndrome Ovarian Stimulation Ovidrel Patients PRIME protocol Progesterone Progestins Sperm Ultrasonography Uterus Woman
3
Ovarian Stimulation and IVF Protocols
Conventional agonist or antagonist stimulation protocols were used for ovarian stimulation as previously described (Cai et al., 2017 (link)). The initial and ongoing dosage was determined according to patients’ age, antral follicle count (AFC), BMI, and ovarian response. An intramuscular injection of human chorionic gonadotropin (4000–6000 IU, hCG; Livzen, China) or a subcutaneous injection of recombinant human chorionic gonadotropin (250 μg, Ovidrel, Merck-Serono, Switzerland) was administrated for final triggering when at least one follicle reached a mean diameter of 18 mm. Ovum puncture under transvaginal ultrasound guidance for oocyte retrieval was performed 34–36 h after hCG injection.
Routine IVF protocol in our center was carried out (Jiang et al., 2022 (link)). Cumulus-oocyte complexes were co-cultured with approximate 1.5–3 X 105 progressively motile spermatozoa in pre-equilibrated fertilization culture medium (K-SIFM, Cook) under mineral oil in traditional incubators (C200, Labotect) at 37°C, 6% CO2 and 5% O2 in a humidified atmosphere. After 4 h co-culture, oocytes were denuded and cultured individually in preequilibrated Cleavage Medium (K-SICM, Cook). The culture system and the procedure of semen preparation were kept unchanged in the period of study. Fertilization was determined according to the presence of two pronuclei (2 PN) about 17 h post insemination. It should be confirmed 2 h later if no obvious pronuclei could be observed.
Jiang X., Cai J., Liu L., Liu Z., Chen J., Yang C., Chen K., Yang X., Geng J., Ma C., Lian S., Xu L, & Ren J. (2023). Predicting the unexpected total fertilization failure in conventional in vitro fertilization cycles: What is the role of semen quality?. Frontiers in Cell and Developmental Biology, 11, 1133512.
Full text: Click here
Publication 2023
Atmosphere Coculture Techniques Cytokinesis Fertilization fibroblast chemotactic inhibitor Graafian Follicle Human Chorionic Gonadotropin Insemination Intramuscular Injection Oil, Mineral Oocyte Retrieval Oocytes Ovarian Follicle Ovarian Stimulation Ovary Ovidrel Ovum Patients Plant Embryos Punctures Sperm Subcutaneous Injections Ultrasonography
4
Perinatal Outcomes in Blastocyst vs Cleavage Stage Embryo Transfer
The unit of analysis here was a singleton live birth episode resulting from transfer of a fresh blastocyst or cleavage stage ET. As some women had two or more singleton live birth episodes arising from several ETs within the study period, all analyses were conducted under a multilevel framework, which accommodated repeated cycles resulting in livebirths within the same women. In order to account for the dependency between cycles resulting in live birth within women, a population-averaged model using generalized estimating equations was used to explore associations between the exposure groups (blastocyst versus cleavage stage ET) and perinatal outcomes (Hardin and Hilbe, 2003 ) and to estimate 95% CI using robust standard errors that allowed for correlation within women (McCullagh and Nelder, 1989 ). We specified an exchangeable correlation structure, which assumes that the risk of a perinatal adverse event was the same for any live birth within a woman. For the outcomes of preterm birth (preterm birth versus full-term birth), congenital anomaly (yes versus no), and healthy baby status (yes versus no), a robust Poisson regression model was used. For the two birthweight outcome variables (i.e. birthweight coded as low, normal or high, and birthweight adjusted for gestational age coded as SGA, AGA, or LGA), a multinomial logistic regression model was employed since each of these variables had three categories (Chamberlain, 1980 ; Pforr, 2014 ). The association between treatment strategy (blastocyst or cleavage stage ET) and very preterm birth (versus full-term birth) was estimated using multinomial logistic regression (where we also included 32–37 weeks gestation as a nuisance outcome category). Crude risk ratios (RRs), adjusted RRs (aRRs), and 95% CI were calculated. The following factors were considered as confounders: maternal age (years), cause of infertility (i.e. tubal disease, ovulatory disorder, male factor, unexplained), previous pregnancy status (yes/no), treatment type or type of insemination (IVF versus ICSI), number of eggs collected, and year of treatment. The covariates considered for adjustment differed for each of the outcomes and are listed in the footnote under each table. Since ET stage could influence birthweight through its effect on gestational age, gestational age can be considered to be a mediator on the causal pathway from cleavage or blastocyst stage ET to birthweight. Therefore, it was excluded to avoid bias since its inclusion does not allow us to estimate the total direct effect of the stage of ET on birthweight (Wilcox et al., 2011 (link)). In the same way, the number of embryos transferred was considered as a mediator and was excluded from multivariable analyses. Further, congenital anomalies or the underlying cause of congenital anomalies have been linked with iatrogenic preterm birth owing to early induction of labour (Brown, 2009 (link)). In this case, gestational age would be considered a collider rather than a confounder as both ET stage and congenital anomaly can affect gestational age through independent routes. Therefore, gestational age was also excluded from this analysis.
Raja E.A., Bhattacharya S., Maheshwari A, & McLernon D.J. (2023). A comparison of perinatal outcomes following fresh blastocyst or cleavage stage embryo transfer in singletons and twins and between singleton siblings. Human Reproduction Open, 2023(2), hoad003.
Full text: Click here
Publication 2023
Birth Weight Blastocyst Blastocyst Transfer Congenital Abnormality Cytokinesis Eggs Embryo Gestational Age Infant Insemination Labor, Induced Males Ovulation Premature Birth Sperm Injections, Intracytoplasmic Sterility, Reproductive Term Birth Woman
5
Evaluating Pre-pregnancy Risk Factors
Pre-pregnancy complications were defined based on a history of (i) previous three or more early miscarriages [2 ], (ii) previous late miscarriage (after week 16) including IUFD, or for the current pregnancy (iii) ART (IVF, insemination, or other medically or surgical assistance), or (iv) duration exceeding one year to conceive.
Uncomplicated pre-pregnancy was defined as pregnancies with fewer than three prior early miscarriages, no late miscarriage or IUFD, less than one year to conceive and unassisted conception. If a participant did not answer a question needed for this categorization, the answer was considered uncomplicated.
Questions regarding potential risk factors were chosen from the questionnaire to estimate: (i) general health and health seeking behavior (body mass index (BMI), menstruation, cervical screening attendance, eating disorders and gynecological infections), (ii) lifestyle (age, country of birth, education level, work situation, contact with animals, smoking, mouth tobacco use and diet), (iii) drugs (drug use before pregnancy: asthma and allergy medication, anxiety, antidepressants and sleep medication, prescription free pain medication, opioids and strong pain medication, thyroid medication, blood pressure medication, stomach acid medication and other medication), (iv) reproductive health (first pregnancy and contraceptive use) and (v) comorbidities (diagnosed and suspected endometriosis and polycystic ovary syndrome (PCOS)) (Supplement 1). Participants were sorted as having suspected PCOS if they reported Ferriman-Gallwey score ≥ 8 [14 (link)] or hair loss grade 3, and suspected endometriosis if they reported vaginal spotting before the start of menstruation [15 (link), 16 (link)].
Gudnadottir U., Du J., Hugerth L.W., Engstrand L., Schuppe-Koistinen I., Wiberg Itzel E., Fransson E, & Brusselaers N. (2023). Pre-pregnancy complications - associated factors and wellbeing in early pregnancy: a Swedish cohort study. BMC Pregnancy and Childbirth, 23, 153.
Full text: Click here
Publication 2023
Alopecia Animals Antidepressive Agents Anxiety Asthma Blood Pressure Childbirth Conception Contraceptive Agents Diet Drug Allergy Eating Disorders Endometriosis Gastric Acid Index, Body Mass Infection Insemination Menstruation Miscarriage Neck Operative Surgical Procedures Opioids Oral Cavity Pain Pharmaceutical Preparations Polycystic Ovary Syndrome Pregnancy Pregnancy Complications Prescription Drugs Sleep Spontaneous Abortion Thyroid Gland Vagina

Top products related to «Insemination»

1
Gonal f by Merck Group
Sourced in Switzerland, Germany, Italy, France, United States, Spain, Netherlands, United Kingdom, Australia, Japan, Denmark, Brazil, China
Gonal-F is a recombinant human follicle-stimulating hormone (r-hFSH) produced by recombinant DNA technology. It is used as a fertility medication to stimulate follicular development and maturation in the ovary as part of an assisted reproductive technology (ART) program.
2
Hyaluronidase by Merck Group
Sourced in United States, Germany, Switzerland, United Kingdom, Japan, China, Italy, France, Macao, Israel, Australia, Sao Tome and Principe, Canada, Spain, Netherlands, Czechia
Hyaluronidase is an enzyme used in laboratory settings. It functions by breaking down hyaluronic acid, a component of the extracellular matrix.
3
Ovoil by Vitrolife
Sourced in Sweden, United States, Japan, Canada
Ovoil is a sterile, medical grade mineral oil designed for use in assisted reproductive technologies. It is an essential component in various laboratory procedures, providing an optimal environment for the handling and culture of oocytes and embryos.
4
G1 plus medium by Vitrolife
Sourced in Sweden, Switzerland, Italy
G1-plus medium is a culture medium designed for the incubation and growth of human embryos. It provides the necessary nutrients and conditions to support the development of embryos during in vitro fertilization (IVF) procedures.
5
Bovine serum albumin (bsa) by Merck Group
Sourced in United States, Germany, United Kingdom, China, Italy, Japan, France, Sao Tome and Principe, Canada, Macao, Spain, Switzerland, Australia, India, Israel, Belgium, Poland, Sweden, Denmark, Ireland, Hungary, Netherlands, Czechia, Brazil, Austria, Singapore, Portugal, Panama, Chile, Senegal, Morocco, Slovenia, New Zealand, Finland, Thailand, Uruguay, Argentina, Saudi Arabia, Romania, Greece, Mexico
Bovine serum albumin (BSA) is a common laboratory reagent derived from bovine blood plasma. It is a protein that serves as a stabilizer and blocking agent in various biochemical and immunological applications. BSA is widely used to maintain the activity and solubility of enzymes, proteins, and other biomolecules in experimental settings.
6
Menopur by Ferring
Sourced in Switzerland, Germany, United States, Denmark, Canada, Belgium, Spain, China, France, Sweden, United Kingdom
Menopur is a medication used in assisted reproductive technology (ART) procedures. It contains a mixture of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), which are hormones that play a crucial role in the development and maturation of ovarian follicles.
7
Ovidrel by Merck Group
Sourced in Switzerland, Germany, Italy, United States, Brazil, Australia
Ovidrel is a laboratory product manufactured by Merck Group. It is a recombinant human chorionic gonadotropin (hCG) medication used for in vitro fertilization (IVF) procedures. Ovidrel is designed to trigger the final stage of egg maturation prior to ovulation.
8
Duphaston by Abbott
Sourced in United States, Netherlands
Duphaston is a pharmaceutical product manufactured by Abbott. It is a synthetic progestogen used as a hormonal supplement.
9
Ovitrelle by Merck Group
Sourced in Germany, Switzerland, France, Italy, United Kingdom, Netherlands
Ovitrelle is a laboratory product manufactured by Merck Group. It is a gonadotropin-releasing hormone agonist used in in-vitro fertilization procedures.
10
G 1 plus by Vitrolife
Sourced in Sweden, Australia, United States
The G-1 PLUS is an embryo culture medium developed by Vitrolife for use in assisted reproductive technology. It is a formulation of nutrients, energy substrates, and other components designed to support the in vitro culture of human embryos.

More about "Insemination"

Insemination is the process of introducing semen into the female reproductive tract, often for the purpose of achieving pregnancy.
This can be done through various methods, such as artificial insemination (AI), in which semen is collected and then injected into the uterus or cervix, or natural insemination, which involves sexual intercourse.
Insemination is a common technique used in assisted reproductive technologies (ART), as well as in animal breeding programs.
It is an important area of study for researchers interested in improving fertility and reproductive outcomes.
Researchers may also find insights from the use of fertility medications like Gonal-F, Menopur, Ovidrel, and Duphaston, which are sometimes used in conjunction with insemination procedures.
Additionally, the use of media like G1-plus and G-1 PLUS, as well as supplements like Hyaluronidase and Bovine serum albumin, can be relevant to insemination research.
PubCompare.ai's AI-driven protocol comparison tool can help optimize insemination research by providing a streamlined way to locate and analyze insemination protocols from literature, pre-prints, and patents.
This intelligent system can help researchers identify the best options for their insemination studies, saving time and improving the efficiency of their research efforts.
Whether you're studying natural insemination, artificial insemination, or the use of fertility medications and media in insemination procedures, the wealth of information available on insemination can be a valuable resource for researchers in this field.
By leveraging the insights and tools available, you can enhance your insemination research and drive progress in improving fertility and reproductive outcomes.